1-3 of 3
Jordi Rodón
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodon, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson
Journal: Cancer Discovery
Cancer Discov (2023) 13 (11): 2412–2431.
https://doi.org/10.1158/2159-8290.CD-23-0669
Published: 01 November 2023
View article titled, MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <em>MTAP</em>-Deleted Cancer
Open the PDF for MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <em>MTAP</em>-Deleted Cancer in another window
Includes: Supplementary data
Journal Articles

Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness

Jordi Rodon, Josep Tabernero
Journal: Cancer Discovery
Cancer Discov (2017) 7 (7): 666–669.
https://doi.org/10.1158/2159-8290.CD-17-0500
Published: 05 July 2017
View article titled, Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
Open the PDF for Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness in another window
Journal Articles

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Yasir H. Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres-Lockhart, Aleix Prat, Pilar Anton, Patricia Cozar, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maria Teresa Calvo, Claudia Aura, Orland Díez, Isabel T. Rubio, José Pérez, Jordi Rodón, Javier Cortés, Leif W. Ellisen, Maurizio Scaltriti, José Baselga
Journal: Cancer Discovery
Cancer Discov (2012) 2 (11): 1036–1047.
https://doi.org/10.1158/2159-8290.CD-11-0348
Published: 11 November 2012
View article titled, PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Open the PDF for PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition in another window
Includes: Supplementary data